<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680441</article-id><article-id pub-id-type="doi">10.3390/v16121830</article-id><article-id pub-id-type="publisher-id">viruses-16-01830</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Association Between Cytomegalovirus Infection and Kidney Damage in the Liver Transplant Setting</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8294-3560</contrib-id><name><surname>Ossami Saidy</surname><given-names>Ramin Raul</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-viruses-16-01830" ref-type="aff">1</xref><xref rid="c1-viruses-16-01830" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Eurich</surname><given-names>Franziska</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-viruses-16-01830" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1482-6255</contrib-id><name><surname>Globke</surname><given-names>Brigitta</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-viruses-16-01830" ref-type="aff">1</xref><xref rid="af2-viruses-16-01830" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Sch&#x000f6;ning</surname><given-names>Wenzel</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-viruses-16-01830" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4499-1673</contrib-id><name><surname>&#x000d6;llinger</surname><given-names>Robert</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-viruses-16-01830" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5074-7063</contrib-id><name><surname>Raschzok</surname><given-names>Nathanael</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><xref rid="af1-viruses-16-01830" ref-type="aff">1</xref><xref rid="af2-viruses-16-01830" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Pratschke</surname><given-names>Johann</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-viruses-16-01830" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Eurich</surname><given-names>Dennis</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-viruses-16-01830" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Dittrich</surname><given-names>Luca</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-viruses-16-01830" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1616-9826</contrib-id><name><surname>Dobrindt</surname><given-names>Eva Maria</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-viruses-16-01830" ref-type="aff">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Ho</surname><given-names>Dora</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Tayyar</surname><given-names>Ralph</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-16-01830"><label>1</label>Department of Surgery, Campus Virchow Klinikum and Campus Charit&#x000e9; Mitte, Charit&#x000e9;&#x02013;Universit&#x000e4;tsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany; <email>franziska.eurich@alumni.charite.de</email> (F.E.); <email>brigitta.globke@charite.de</email> (B.G.); <email>wenzel.schoening@charite.de</email> (W.S.); <email>robert.oellinger@charite.de</email> (R.&#x000d6;.); <email>nathanael.raschzok@charite.de</email> (N.R.); <email>johann.pratschke@charite.de</email> (J.P.); <email>dennis.eurich@charite.de</email> (D.E.); <email>luca.dittrich@charite.de</email> (L.D.); <email>eva-maria.dobrindt@charite.de</email> (E.M.D.)</aff><aff id="af2-viruses-16-01830"><label>2</label>Berlin Institute of Health at Charit&#x000e9;&#x02014;Universit&#x000e4;tsmedizin Berlin, BIH Academy, Clinician Scientist Program, 10117 Berlin, Germany</aff><author-notes><corresp id="c1-viruses-16-01830"><label>*</label>Correspondence: <email>ramin-raul.ossami-saidy@charite.de</email></corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1830</elocation-id><history><date date-type="received"><day>01</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>19</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Introduction: The development of chronic kidney disease (CKD) is a common and significant complication, contributing to morbidity after liver transplantation (LT). Cytomegalovirus (CMV) infection is common in the overall population, and relevant reinfection after LT may occur. CMV-associated kidney damage has been discussed, but the clinical significance on CKD development after LT remains unclear. Methods: A total of 745 patients who underwent LT between 2006 and 2017 were included in this retrospective analysis. Clinical data, as well as laboratory parameters, were analyzed. Univariate and multivariate analysis were performed. Results: The univariate analysis revealed significantly impaired estimated glomerular filtration rates (eGFRs) in patients with histories of CMV infection (81.4 (8&#x02013;137) mL/min vs. 90.0 (5&#x02013;147) mL/min; <italic toggle="yes">p</italic> = 0.004). This effect was confirmed in the multivariate analysis. Post-LT, eGFR was impaired in patients with CMV (re)infection at 6, 12, 36, and 60 months, 10 years, and 15 years after LT. Immunosuppressive levels were comparable between groups. Overall survival was negatively affected by CMV infection (<italic toggle="yes">p</italic> = 0.001). Discussion: A clinically significant detrimental impact of CMV infection on renal function was observed, that could individualize clinical risk evaluation prior and after LT further. However, the pathophysiological mechanisms behind this observation are not yet understood.</p></abstract><kwd-group><kwd>liver transplantation</kwd><kwd>cytomegalovirus</kwd><kwd>chronic kidney disease</kwd><kwd>immunosuppression</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01830"><title>1. Introduction</title><p>Liver transplantation (LT) remains the only curative therapeutic option for various end-stage liver diseases (ESLDs) [<xref rid="B1-viruses-16-01830" ref-type="bibr">1</xref>,<xref rid="B2-viruses-16-01830" ref-type="bibr">2</xref>].</p><p>Post LT, lifelong immunosuppression (IS) remains standard therapy to prevent rejection episodes. IS itself is associated with short- and long-term complications such as chronic kidney disease (CKD), metabolic diseases, cardiovascular events, opportunistic infections, and malignancies [<xref rid="B3-viruses-16-01830" ref-type="bibr">3</xref>,<xref rid="B4-viruses-16-01830" ref-type="bibr">4</xref>,<xref rid="B5-viruses-16-01830" ref-type="bibr">5</xref>,<xref rid="B6-viruses-16-01830" ref-type="bibr">6</xref>,<xref rid="B7-viruses-16-01830" ref-type="bibr">7</xref>,<xref rid="B8-viruses-16-01830" ref-type="bibr">8</xref>,<xref rid="B9-viruses-16-01830" ref-type="bibr">9</xref>,<xref rid="B10-viruses-16-01830" ref-type="bibr">10</xref>].</p><p>Renal dysfunction and the diagnosis of CKD prior to LT have been established as independent risk factors for poorer outcomes after LT [<xref rid="B11-viruses-16-01830" ref-type="bibr">11</xref>]. Via the hepatorenal pathway, kidney function can be impaired by the underlying liver disease and is therefore part of scoring systems, such as the Model for End-stage Liver Disease (MELD) [<xref rid="B12-viruses-16-01830" ref-type="bibr">12</xref>,<xref rid="B13-viruses-16-01830" ref-type="bibr">13</xref>]. Thus, the presence of CKD after LT is common and multifaceted, caused by liver disease itself and aggravated by, e.g., immunosuppression and decreasing renal function due to age [<xref rid="B14-viruses-16-01830" ref-type="bibr">14</xref>,<xref rid="B15-viruses-16-01830" ref-type="bibr">15</xref>]. Importantly, CKD has been linked to increased morbidity and decreased survival in patients [<xref rid="B16-viruses-16-01830" ref-type="bibr">16</xref>,<xref rid="B17-viruses-16-01830" ref-type="bibr">17</xref>,<xref rid="B18-viruses-16-01830" ref-type="bibr">18</xref>].</p><p>CMV infection, as well as reactivation, after LT is one of the most relevant infections and it contributes to increases in morbidity and mortality [<xref rid="B10-viruses-16-01830" ref-type="bibr">10</xref>,<xref rid="B19-viruses-16-01830" ref-type="bibr">19</xref>]. CMV serostatus mismatch of LT donors and recipients has been established as a risk factor for reoccurring infection, and recommendations on the administration of pharmaceutical prophylaxis are based upon these laboratory findings [<xref rid="B20-viruses-16-01830" ref-type="bibr">20</xref>,<xref rid="B21-viruses-16-01830" ref-type="bibr">21</xref>,<xref rid="B22-viruses-16-01830" ref-type="bibr">22</xref>]. CMV infection in healthy, immunocompetent individuals commonly resolves with only minor symptoms, but critically ill, immunocompromised patients are at heightened risk for severe courses [<xref rid="B23-viruses-16-01830" ref-type="bibr">23</xref>,<xref rid="B24-viruses-16-01830" ref-type="bibr">24</xref>,<xref rid="B25-viruses-16-01830" ref-type="bibr">25</xref>]. The range of manifestations of CMV infections is wide, with uncharacteristic symptoms such as fever in addition to colitis, encephalitis, pneumonitis, and nephritis with proteinuria [<xref rid="B24-viruses-16-01830" ref-type="bibr">24</xref>,<xref rid="B26-viruses-16-01830" ref-type="bibr">26</xref>].</p><p>Impairment of graft function in kidney transplant (KT) patients with CMV infection is generally recognized, but its mechanism is not fully understood and ranges from induction of rejection to endothelial alterations [<xref rid="B27-viruses-16-01830" ref-type="bibr">27</xref>]. Interestingly, CMV infection has been linked to increase arterial stiffness in CKD patients [<xref rid="B28-viruses-16-01830" ref-type="bibr">28</xref>]. The extent to which glomerulopathy is caused by CMV infection in non-KT patients remains disputed, and its clinical significance is unknown [<xref rid="B29-viruses-16-01830" ref-type="bibr">29</xref>,<xref rid="B30-viruses-16-01830" ref-type="bibr">30</xref>,<xref rid="B31-viruses-16-01830" ref-type="bibr">31</xref>,<xref rid="B32-viruses-16-01830" ref-type="bibr">32</xref>,<xref rid="B33-viruses-16-01830" ref-type="bibr">33</xref>].</p><p>To our knowledge, the significance of CMV infection in the development of CKD in LT patients has not been thoroughly studied. This work aims to explore the potential link between CMV infection and renal dysfunction in LT patients and to contextualize these findings within long-term outcomes following LT.</p></sec><sec id="sec2-viruses-16-01830"><title>2. Materials and Methods</title><p>All adult patients undergoing LT at a single transplant center between 2006 and 2017 were considered for this retrospective study. Follow-up for this study was ended in 12/2023. Patients with multiorgan transplantation, re-transplantation, and missing data were excluded.</p><p>Clinical and laboratory parameters, such as MELD score, CMV serostatus of donor and recipient, dosage and trough levels of IS, estimated glomerular filtration rate (eGFR) prior to LT, and clinical course after LT, were extracted from our prospectively maintained database. Life-long follow-up after LT was ensured via our outpatient clinic according to a standardized schedule ranging from twice a week to every three months, depending on time after LT. Renal function was assessed preoperatively within one month prior to LT and 6, 12, 36, 60, 120, and 180 months after LT. Classification of CKD was conducted using the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for eGFRs [<xref rid="B34-viruses-16-01830" ref-type="bibr">34</xref>]. To further analyze the course of renal function, loss of eGFR was calculated by subtracting the means of the eGFRs.</p><p>To analyze comorbidities relevant to the development of CKD, the presence of &#x0201c;cardiovascular disease&#x0201d; was stated when patients were diagnosed with arterial hypertension on medication or atherosclerosis (e.g., coronary sclerosis, peripheral arterial disease). Similarly, &#x0201c;diabetes&#x0201d; was acknowledged if patients received antidiabetic drug treatment. Age at time of LT was dichotomized into &#x02264;60 and &#x0003e;60 years.</p><p>CMV infection after LT was diagnosed by positive CMV-DNA-PCR, and was classified as follows: (i) CMV viremia in asymptomatic patients; (ii) CMV syndrome in patients with typical signs and symptoms of the disease; (iii) histologically proven tissue-invasive CMV infection.</p><p>CMV prophylaxis consisted of acyclovir or valganciclovir (VGCV) and was administered as part of standard of care according to donor/recipient CMV-IgG constellation up to 6 months after LT [<xref rid="B35-viruses-16-01830" ref-type="bibr">35</xref>]. Routinely, preemptive therapy was conducted in new-onset viremia, but individual factors were acknowledged.</p><p>IS was administered in an individualized manner due to patients&#x02019; risk profiles and comorbidities. Standard regimen consisted of calcineurine inhibitors (CNI; tacrolimus, cyclosporin A) with the addition of, e.g., mycophenolate mofetil (MMF), mammalian target of rapamycin inhibitors (mTORI), or glucocorticoids (GCs). GCs were routinely administered after transplantation and tapered until 12 weeks after LT. We focused on dosage and trough levels of tacrolimus and these values were analyzed within 2 weeks and 3, 6, 12, 36, 60, and 120 months after LT. Cumulative dosage was calculated by using the area under the curve (AUC). The impact of cumulative dosage on renal function was calculated using the 50th percentile for each time point and, accordingly, patients were subsumed into a &#x0201c;low exposure&#x0201d; group and a &#x0201c;high exposure&#x0201d; group. </p><p>For descriptive analysis, absolute numbers (<italic toggle="yes">n</italic>) with percentages (%) were given with mean and standard deviation (SD) for normally distributed variables, or they were given as median with minimum and maximum for non-normally distributed variables. Cross tables were used in nominal variables and a <italic toggle="yes">t</italic>-test was used for normally distributed continuous variables. In cases of non-normally distributed values, a Mann&#x02013;Whitney U-test or a Kruskal&#x02013;Wallis test were performed. Pearson correlation was applied for metric variables. ANOVA was applied for the comparative analysis of multiple groups. For multivariate analysis, multinominal logistic regression was used to evaluate effect strength, and regression coefficient (&#x003b2;) and confidence interval (CI) were calculated. A two-sided <italic toggle="yes">p</italic>-value of &#x0003c;0.05 was considered significant. Statistical analysis was performed using SPSS Statistics Version 26.0 (IBM Co., Armonk, New York, NY, USA). Figures were created using SPSS and Microsoft Excel 2016. This study was approved by the ethics committee of Charit&#x000e9; Universit&#x000e4;tsmedizin, Berlin (protocol code EA1/255/20; date of approval: 20 October 2020).</p></sec><sec sec-type="results" id="sec3-viruses-16-01830"><title>3. Results</title><sec id="sec3dot1-viruses-16-01830"><title>3.1. Cohort Characteristics</title><p>Overall, 745 patients undergoing LT between 2006 and 2017 were included in this study. The majority, 494 patients (66.3%), were male and the median age at transplantation was 56.3 (19.3&#x02013;74.2) years. Median eGFR prior to LT was 84.80 (5&#x02013;150) mL/min.</p><p>IS after LT was mainly CNI-based (<italic toggle="yes">n</italic> = 725/97.3%). At the end of follow-up, 313 (42.0%) patients were deceased and median survival after LT was 121.0 (6&#x02013;213) months. For details on the patient cohort, see <xref rid="viruses-16-01830-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec3dot2-viruses-16-01830"><title>3.2. CMV Infection and Renal Function Prior to LT</title><p>Patients with positive CMV-IgG serostatus showed significantly lower median eGFR than patients without prior CMV infection (<italic toggle="yes">p</italic> = 0.004). Patients aged &#x02264;60 had higher median eGFR compared to patients &#x0003e; 60 years (<italic toggle="yes">p</italic> = 0.011). Female patients showed significantly lower median eGFR (<italic toggle="yes">p</italic> &#x0003c; 0.001). Presence of cardiovascular disease at LT was also significantly associated with lower median eGFR (<italic toggle="yes">p</italic> &#x0003c; 0.001). Furthermore, the underlying disease leading to LT was associated with significant differences in median eGFR. MELD score showed statistically significant inverse correlation with eGFR (r = &#x02212;0.323, <italic toggle="yes">p</italic> &#x0003c; 0.001). For details of variables, see <xref rid="viruses-16-01830-t002" ref-type="table">Table 2</xref>.</p><p>Analysis of influence on kidney function prior to LT according to CKD stage showed similar results. However, distribution of renal function according to CKD classification did not significantly differ with regard to prior CMV infection (<italic toggle="yes">p</italic> = 0.059); for details, see <xref rid="viruses-16-01830-t002" ref-type="table">Table 2</xref>.</p><p>Multivariate analysis confirmed significantly higher eGFR in patients &#x0003c; 60 years (<italic toggle="yes">p</italic> &#x0003c; 0.001) at LT and male patients (<italic toggle="yes">p</italic> &#x0003c; 0.001). EGFR was significantly lower in patients diagnosed with cardiovascular disease (<italic toggle="yes">p</italic> = 0.004) and higher MELD score (<italic toggle="yes">p</italic> &#x0003c; 0.001) in this analysis. CMV infection prior to LT did not show any statistically significant association with eGFR levels (see <xref rid="viruses-16-01830-t003" ref-type="table">Table 3</xref>).</p></sec><sec id="sec3dot3-viruses-16-01830"><title>3.3. CMV Infection and Renal Function Post LT</title><p>EGFR after LT showed a slight increase within 6 months from a median of 84.80 (5&#x02013;150) mL/min prior to LT to 86.2 (8&#x02013;139) mL/min (<italic toggle="yes">p</italic> &#x0003e; 0.001) and a continuous decrease in the following years to 61.0 (5&#x02013;118) mL/min after ten years. Statistically significant inverse correlation of MELD score and eGFR was found 6 and 12 months after LT (<italic toggle="yes">p</italic> = 0.008 and <italic toggle="yes">p</italic> = 0.006, respectively) but not at a later timepoint. Using the CKD classification, significantly higher MELD scores were observed in patients with declining kidney function 6 and 12 months (<italic toggle="yes">p</italic> = 0.002 and <italic toggle="yes">p</italic> = 0.002) after LT but not at a later point in time. </p><p>Statistically significant decreased eGFR was observed in patients with post-LT CMV infection 6 months (<italic toggle="yes">p</italic> = 0.002), 12 months (<italic toggle="yes">p</italic> = 0.024), 36 months (<italic toggle="yes">p</italic> = 0.003), 60 months (<italic toggle="yes">p</italic> = 0.001), 10 years (<italic toggle="yes">p</italic> = 0.037), and 15 years (<italic toggle="yes">p</italic> = 0.032) after LT. Of note, comparison of these groups showed significantly higher eGFR prior to LT in patients without post-LT CMV infections (87.5 (5&#x02013;150) vs. 79.9 (10&#x02013;137) mL/min, <italic toggle="yes">p</italic> = 0.007). Total difference in median eGFR was 3.75 mL/min 6 months after LT and increased to 6.9 mL/min after 5 years and to 6 and 32 mL/min after 10 and 15 years, respectively.</p><p>Using the CKD classification, similar results were found: patients with post-LT CMV infection showed significantly higher stages at 6 months (CKD stage &#x0003e; 2: 80 (17.3%) vs. 68 (26.0%), <italic toggle="yes">p</italic> = 0.006), 3 years (CKD stage &#x0003e; 2: 75 (19.6%) vs. 60 (29.3%), <italic toggle="yes">p</italic> = 0.05), and 5 years (CKD stage &#x0003e; 2: 72 (22.6%) vs. 61 (36.5%), <italic toggle="yes">p</italic> = 0.008) after transplantation.</p><p>No difference between these two groups were found regarding age, sex, cardiovascular disease, or diabetes. Indication leading to LT showed fewer alcoholic ESLD (41.4% vs. 39.9%) and viral hepatitis (25.9% vs. 16.6%) patients developing post-LT CMV infection than patients with autoimmune diseases (12.2% vs. 14.4%) and cryptogenic cirrhosis (5.9% vs. 11.1%) (<italic toggle="yes">p</italic> = 0.003). Patients who developed a post-LT CMV infection had a higher median MELD score (14 (6&#x02013;44)) vs. 18 (6&#x02013;48), <italic toggle="yes">p</italic> &#x0003c; 0.001).</p><p>No difference was found in regard to the extent of infection (viremia vs. syndrome vs. tissue invasion) and kidney function at any time point, neither through analyzing eGFR nor CKD stages. The extent of viremia was not associated with changes in eGFR or CKD stage at any time point. A subgroup analysis of 47 patients with more than one episode of new viremia after LT vs. 224 patients with only one episode of post-LT CMV infection showed that statistically lower eGFRs were only present ten years after transplant. Here, multiple recurrent infections were associated with lower eGFR (58.0 (16&#x02013;118) vs. 40.0 (8&#x02013;95) mL/min, <italic toggle="yes">p</italic> = 0.018). All patients with more than one episode of post-LT CMV infection were deceased 15 years after LT.</p><p>For further analysis, three groups were defined: group 1&#x02014;patients with CMV-negative serostatus at the time of LT and no recorded post-LT CMV infection; group 2&#x02014;patients with seropositive CMV status at the time of LT without post-LT CMV infection; group 3&#x02014;all patients with post-LT CMV infection regardless of the preoperative serostatus (see <xref rid="viruses-16-01830-f001" ref-type="fig">Figure 1</xref>).</p><p>No difference was observed between groups regarding age, sex, or comorbidities, but MELD score was different with 13 (6&#x02013;40) in group 1, 15 (6&#x02013;40) in group 2, and 18 (6&#x02013;40) in group 3 (<italic toggle="yes">p</italic> &#x0003c; 0.001).</p><p>eGFR between these groups differed prior to LT with statistical significance, as group 1 showed better median eGFR with 90.0 (5&#x02013;150) mL/min than group 2, with a median eGFR of 84.3 (8&#x02013;137) mL/min, and group 3 with 79.9 (10&#x02013;137) mL/min (<italic toggle="yes">p</italic> = 0.005). This observation remained statistically significant throughout the follow-up of 6 months, 3 years, and 5 years (<italic toggle="yes">p</italic> = 0.005, <italic toggle="yes">p</italic> = 0.011, and <italic toggle="yes">p</italic> = 0.005, respectively). In the long-term follow-up, however, 10 and 15 years after LT, this effect did not reach statistical significance anymore (<italic toggle="yes">p</italic> = 0.11 and <italic toggle="yes">p</italic> = 0.11, respectively).</p><p>Analyzing renal function using the CKD classification showed no statistically significant differences in the distribution of the CKD stages between the groups at the time of transplant (<italic toggle="yes">p</italic> = 0.071). Six months after LT, CKD stages &#x02265; 3 were found more frequently in group 3 (25.9%) vs. group 2 (17.5%) or group 1 (17.0%) (<italic toggle="yes">p</italic> = 0.015). This statistically significant difference in CKD stages was not found at the timepoints of 1 and 3 years, but was found again at 5 years (<italic toggle="yes">p</italic> = 0.038) after LT. For details on the course of eGFR, see <xref rid="viruses-16-01830-f002" ref-type="fig">Figure 2</xref> and <xref rid="app1-viruses-16-01830" ref-type="app">Supplementary Materials, Table S1</xref>.</p></sec><sec id="sec3dot4-viruses-16-01830"><title>3.4. Immunosuppression and Renal Function</title><p>To assess the impact of immunosuppression on kidney damage, the dosage of CNI was compared between groups. Mean tacrolimus trough level as well as cumulative dosage showed no difference between patients with or without CMV infection after LT at any time point. Cross-testing of dichotomized cumulative dosage was conducted, using the 50th percentile as the cut-off; here, statistically significantly lower dosages were found more frequently in the patients with CMV infection at 6 months after LT (<italic toggle="yes">p</italic> = 0.009) but not beyond.</p><p>Comparison of patients with no CMV infection (group 1), patients with CMV seropositivity only (group 2), and those with CMV infection (group 3) also showed no significant difference in mean tacrolimus trough level or cumulative exposure to CNI. Here, dichotomized tacrolimus exposure again revealed the lowest cumulative tacrolimus dosage in group 3 with statistical significance only at 6 months and 12 months after LT (<italic toggle="yes">p</italic> = 0.015, <italic toggle="yes">p</italic> = 0.014).</p><p>Analysis of &#x0201c;low&#x0201d; or &#x0201c;high&#x0201d; tacrolimus exposure and CKD classification showed significant differences between these groups only 12 months after LT: here, the group of &#x0201c;low exposure&#x0201d; consisted of more patients with impaired renal function (CKD &#x0003e; 1, <italic toggle="yes">p</italic> = 0.011). No difference in eGFR was found at any time point after LT between patients undergoing rejection prophylaxis with monotherapy or combination therapy. Analysis of IS regimen (monotherapy vs. combination therapy) showed no significant differences on CMV occurrence after LT. Usage of mTORI in IS regimen revealed a trend towards decreased CMV infections (<italic toggle="yes">n</italic> = 25 (28.7%) vs. <italic toggle="yes">n</italic> = 246 (37.6%), <italic toggle="yes">p</italic> = 0.067).</p></sec><sec id="sec3dot5-viruses-16-01830"><title>3.5. CMV Infection and Overall Survival</title><p>Median survival after LT was significantly longer in seropositive CMV (CMV + R) patients prior to LT compared to seronegative recipients (128.0 (6&#x02013;213) vs. 110.5 (6&#x02013;113) months, <italic toggle="yes">p</italic> = 0.048). However, CMV infection after LT was associated with an impaired overall survival of 114.0 (0&#x02013;210) compared to 126.5 (6&#x02013;213) months (<italic toggle="yes">p</italic> = 0.001). This observation was confirmed using a Kaplan&#x02013;Meier analysis (Log rank 0.047). A similar difference was found between the three groups. Patients with a history of CMV infection prior to LT (group 2) had the highest median survival of 129.0 (6&#x02013;213) months, followed by patients without any CMV infection at all with 117.0 (7&#x02013;213) months. Patients with CMV infection after LT (group 3) showed shortest median survival of 114.0 (6&#x02013;210) months (<italic toggle="yes">p</italic> = 0.003). In Kaplan&#x02013;Meier analysis, this observation did not reach statistical significance (<italic toggle="yes">p</italic> = 0.12). Patients with more than one CMV infection after LT also showed decreased median survival (81.0 (6&#x02013;177) vs. 120.5 (6&#x02013;210) months, <italic toggle="yes">p</italic> = 0.001), and this effect was confirmed in the Kaplan&#x02013;Meier analysis (log-rank &#x0003c; 0.001) (see also, <xref rid="viruses-16-01830-f003" ref-type="fig">Figure 3</xref>). Malignancies were the most common cause of death in groups 1 (58.2%) and 2 (45.9%), whereas infections were the most common cause of death in group 3 (34.3%, <italic toggle="yes">p</italic> = 0.029). MELD score did not correlate with overall survival (<italic toggle="yes">p</italic> = 0.815).</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-16-01830"><title>4. Discussion</title><p>In this study, reporting on 745 LT patients from a single center, a significant impact of CMV infection after LT and reduced kidney function was found up to 15 years after transplantation.</p><p>Reduced glomerular filtration rate was observed in patients with a history of CMV infection prior to LT, as defined by IgG positivity in univariate but not multivariate analysis. Other potentially confounding factors (age, sex, indication for LT) also showed significant association to reduced kidney function, but diagnosis of diabetes at the time of transplantation did not. However, we did not assess the severity of diabetes (e.g., insulin dependency) or new-onset diabetes during follow-up. Of note, we found a strong correlation of MELD score and renal function up to 12 months after LT but not on overall survival. Correspondingly, higher MELD scores have been associated with more frequent acute kidney injury and even increased short-term mortality after LT [<xref rid="B36-viruses-16-01830" ref-type="bibr">36</xref>,<xref rid="B37-viruses-16-01830" ref-type="bibr">37</xref>,<xref rid="B38-viruses-16-01830" ref-type="bibr">38</xref>].</p><p>In this study, CMV-IgG-positive patients showed lower eGFR prior to LT compared to those without. Prevalence of CMV worldwide is high, ranging between 50 and 100%, and infection is usually successfully controlled by the immune system in the immunocompetent population [<xref rid="B39-viruses-16-01830" ref-type="bibr">39</xref>,<xref rid="B40-viruses-16-01830" ref-type="bibr">40</xref>]. Of note, CMV serology cannot predict immunity [<xref rid="B41-viruses-16-01830" ref-type="bibr">41</xref>]. Furthermore, reduced renal function in patients with ESLD is common and associated with impaired outcome [<xref rid="B11-viruses-16-01830" ref-type="bibr">11</xref>]. While only few reports of CMV-related kidney damage in immunocompetent patients exist, a link to glomerulopathy and arterial stiffness has been made [<xref rid="B28-viruses-16-01830" ref-type="bibr">28</xref>,<xref rid="B29-viruses-16-01830" ref-type="bibr">29</xref>,<xref rid="B31-viruses-16-01830" ref-type="bibr">31</xref>]. Also, CMV copies in the urine sediment in non-immunocompromised patients with acute kidney injury have been reported [<xref rid="B42-viruses-16-01830" ref-type="bibr">42</xref>]. While renal damage in pre-LT patients is certainly multifaceted, it is noteworthy that ESLD patients can be classified as immunocompromised with dysfunction in both innate and acquired immunity [<xref rid="B43-viruses-16-01830" ref-type="bibr">43</xref>,<xref rid="B44-viruses-16-01830" ref-type="bibr">44</xref>,<xref rid="B45-viruses-16-01830" ref-type="bibr">45</xref>]. CMV seropositive cirrhotic patients have been reported to have an elevated mortality [<xref rid="B46-viruses-16-01830" ref-type="bibr">46</xref>]. The impact of CMV infection before and after LT on the development of CKD in LT patients is not very well known. In this study, significantly reduced eGFR was found in patients with CMV infection after LT and in the group of patients with recurrent CMV exposition compared to CMV-negative patients. However, these groups showed differences in renal function even prior to LT. This might be due to the fact that there is a well-known significant overlap of CMV seropositive patients prior to LT and infection after LT, as CMV seropositivity contributes to a higher rate of reinfection after transplantation [<xref rid="B47-viruses-16-01830" ref-type="bibr">47</xref>,<xref rid="B48-viruses-16-01830" ref-type="bibr">48</xref>,<xref rid="B49-viruses-16-01830" ref-type="bibr">49</xref>]. International recommendations for prophylactic treatment regimens take these risk constellations into account [<xref rid="B20-viruses-16-01830" ref-type="bibr">20</xref>,<xref rid="B48-viruses-16-01830" ref-type="bibr">48</xref>,<xref rid="B50-viruses-16-01830" ref-type="bibr">50</xref>,<xref rid="B51-viruses-16-01830" ref-type="bibr">51</xref>]. No association between amounts of episodes of CMV viremia after LT or extent of CMV infection and kidney damage was observed in this cohort. Given the relatively low numbers of patients in the group of CMV syndrome (<italic toggle="yes">n</italic> = 66) and tissue invasion (<italic toggle="yes">n</italic> = 2), the effect of extent of CMV infection might have been missed in statistical analysis. Additionally, the CMV-induced renal damage might not be connected to the typical clinical presentation of the infection.</p><p>The mechanism and dynamics of the hypothesized CMV-induced damage on glomeruli remain unclear and were not investigated in this work. However, results from this study and clinical data would rather suggest a &#x0201c;slow-burning&#x0201d; processes linked to pathophysiology with subclinical manifestation rather than fulminant kidney injury. This is supported by findings of persistent elevated mortality in patients with CMV infection after liver or kidney transplantation in the long-term setting, despite the early occurrence of infection post-transplantation [<xref rid="B52-viruses-16-01830" ref-type="bibr">52</xref>,<xref rid="B53-viruses-16-01830" ref-type="bibr">53</xref>,<xref rid="B54-viruses-16-01830" ref-type="bibr">54</xref>]. Direct glomerulopathy as well as, e.g., affection of vessels, has been proposed to contribute to kidney damage in CMV infection [<xref rid="B55-viruses-16-01830" ref-type="bibr">55</xref>,<xref rid="B56-viruses-16-01830" ref-type="bibr">56</xref>,<xref rid="B57-viruses-16-01830" ref-type="bibr">57</xref>,<xref rid="B58-viruses-16-01830" ref-type="bibr">58</xref>]. Others have evaluated CMV-induced glomerulopathy rather as episodes or manifestation of rejection that have been misidentified in the context of KT patients [<xref rid="B59-viruses-16-01830" ref-type="bibr">59</xref>]. As mentioned above, in LT patients, negative effects of CMV infection are widely known, but the affection of the kidney is not the focus [<xref rid="B47-viruses-16-01830" ref-type="bibr">47</xref>,<xref rid="B60-viruses-16-01830" ref-type="bibr">60</xref>]. Assessing different &#x0201c;groups at risk&#x0201d; showed clinically relevant impaired kidney function in patients with histories of CMV infection prior to LT and CMV infection after LT, even when compared to those with a history of CMV infection prior to LT only. This might suggest additional, cumulative damage caused by CMV infection, as relevant confounders such as age and sex were ruled out. Certainly, multiple factors contribute to renal damage in an additive maybe even exponential character and especially in multimorbid patients with ESLD or after LT. Weighting of factors is difficult, but CMV infection might mean an additional &#x0201c;hit&#x0201d; in a multifactorial process.</p><p>CNIs, especially tacrolimus, were the backbone IS in this cohort and are known for their dosage-dependent nephrotoxicity [<xref rid="B61-viruses-16-01830" ref-type="bibr">61</xref>]. However, this potentially major confounder was not present in this study, as mean levels and cumulative dosages were not higher in patients with impaired renal function. On the contrary, significantly lower CNI exposure was observed 6 months after LT, indicating proper trough-level-dependent monitoring and individualized adjustment of IS.</p><p>In summary, these findings highlight the importance of prevention of CMV reactivation in the post-transplant setting and underline the effect of individualized regimens in terms of prevention strategies, closely linked to a well-observed individualized immunosuppressive therapy.</p><p>Certain limitations must be mentioned. Although the cohorts mostly represent current standards of diagnostics and treatment, its retrospective nature might have inherited relevant additional confounders in diagnostics and therapeutical concepts that were not exposed and therefore not taken into account in statistical analysis. Renal function prior to LT is certainly affected by various aspects including comorbidities and, e.g., socioeconomic aspects, that were not all assessed in this study. Also, the fundamental question of the pathophysiological mechanisms of CMV-induced renal damage was not explored in this study; thus, at this point, only its clinical observation remains. However, as it seems to be of relevance, current routine laboratory testing is relevant in day-to-day care; patients with new CMV infection and even patients who have undergone CMV infection might profit from further individualized risk stratification.</p></sec><sec sec-type="conclusions" id="sec5-viruses-16-01830"><title>5. Conclusions</title><p>CMV infection before and after LT might contribute to the pathogenesis of CKD in the LT population and therefore play a pivotal role in contributing to major comorbidities that are relevant in the setting of aftercare. However, the pathophysiological mechanisms remain unclear; their identification requires further clinical and experimental research.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-viruses-16-01830"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/v16121830/s1">https://www.mdpi.com/article/10.3390/v16121830/s1</uri>, Table S1: Course of eGFR after LT, dependent on CMV infection.</p><supplementary-material id="viruses-16-01830-s001" position="float" content-type="local-data"><media xlink:href="viruses-16-01830-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, D.E., E.M.D., L.D. and R.R.O.S.; methodology, R.R.O.S., F.E. and L.D.; validation, B.G., R.&#x000d6;. and W.S.; formal analysis, R.R.O.S. and L.D.; investigation, F.E., L.D. and R.R.O.S.; resources, J.P.; data curation, F.E., R.R.O.S., N.R. and D.E.; writing&#x02014;original draft preparation, L.D., R.R.O.S., E.M.D. and D.E.; writing&#x02014;review and editing, B.G., N.R., W.S., R.&#x000d6;. and J.P.; visualization, R.R.O.S. and L.D.; supervision, J.P., E.M.D., D.E. and N.R.; project administration, D.E. and J.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was approved by the ethics committee of Charit&#x000e9; Universit&#x000e4;tsmedizin Berlin (protocol code EA1/255/20; date of approval: 20 October 2020).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy and ethical restrictions and the local institution&#x02019;s data policy.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01830"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mahmud</surname><given-names>N.</given-names></name>
</person-group><article-title>Selection for Liver Transplantation: Indications and Evaluation</article-title><source>Curr. Hepatol. Rep.</source><year>2020</year><volume>19</volume><fpage>203</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1007/s11901-020-00527-9</pub-id><pub-id pub-id-type="pmid">32837824</pub-id>
</element-citation></ref><ref id="B2-viruses-16-01830"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Mehta</surname><given-names>N.N.</given-names></name>
<name><surname>Bojanapu</surname><given-names>S.</given-names></name>
</person-group><article-title>Indication and Contraindications for Liver Transplantation</article-title><source>Peri-Operative Anesthetic Management in Liver Transplantation</source><person-group person-group-type="editor">
<name><surname>Vohra</surname><given-names>V.</given-names></name>
<name><surname>Gupta</surname><given-names>N.</given-names></name>
<name><surname>Jolly</surname><given-names>A.S.</given-names></name>
<name><surname>Bhalotra</surname><given-names>S.</given-names></name>
</person-group><publisher-name>Springer Nature</publisher-name><publisher-loc>Singapore</publisher-loc><year>2023</year><fpage>95</fpage><lpage>104</lpage></element-citation></ref><ref id="B3-viruses-16-01830"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Di Maira</surname><given-names>T.</given-names></name>
<name><surname>Little</surname><given-names>E.C.</given-names></name>
<name><surname>Berenguer</surname><given-names>M.</given-names></name>
</person-group><article-title>Immunosuppression in liver transplant</article-title><source>Best. Pr. Res. Clin. Gastroenterol.</source><year>2020</year><volume>46&#x02013;47</volume><fpage>101681</fpage><pub-id pub-id-type="doi">10.1016/j.bpg.2020.101681</pub-id><pub-id pub-id-type="pmid">33158467</pub-id>
</element-citation></ref><ref id="B4-viruses-16-01830"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cillo</surname><given-names>U.</given-names></name>
<name><surname>De Carlis</surname><given-names>L.</given-names></name>
<name><surname>Del Gaudio</surname><given-names>M.</given-names></name>
<name><surname>De Simone</surname><given-names>P.</given-names></name>
<name><surname>Fagiuoli</surname><given-names>S.</given-names></name>
<name><surname>Lupo</surname><given-names>F.</given-names></name>
<name><surname>Tisone</surname><given-names>G.</given-names></name>
<name><surname>Volpes</surname><given-names>R.</given-names></name>
</person-group><article-title>Immunosuppressive regimens for adult liver transplant recipients in real-life practice: Consensus recommendations from an Italian Working Group</article-title><source>Hepatol. Int.</source><year>2020</year><volume>14</volume><fpage>930</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1007/s12072-020-10091-5</pub-id><pub-id pub-id-type="pmid">33099753</pub-id>
</element-citation></ref><ref id="B5-viruses-16-01830"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaltenborn</surname><given-names>A.</given-names></name>
<name><surname>Schrem</surname><given-names>H.</given-names></name>
</person-group><article-title>Mycophenolate mofetil in liver transplantation: A review</article-title><source>Ann. Transpl.</source><year>2013</year><volume>18</volume><fpage>685</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.12659/aot.889299</pub-id></element-citation></ref><ref id="B6-viruses-16-01830"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spiritos</surname><given-names>Z.</given-names></name>
<name><surname>Abdelmalek</surname><given-names>M.F.</given-names></name>
</person-group><article-title>Metabolic syndrome following liver transplantation in nonalcoholic steatohepatitis</article-title><source>Transl. Gastroenterol. Hepatol.</source><year>2020</year><volume>6</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.21037/tgh.2020.02.07</pub-id></element-citation></ref><ref id="B7-viruses-16-01830"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benvenuto</surname><given-names>L.J.</given-names></name>
<name><surname>Anderson</surname><given-names>M.R.</given-names></name>
<name><surname>Arcasoy</surname><given-names>S.M.</given-names></name>
</person-group><article-title>New frontiers in immunosuppression</article-title><source>J. Thorac. Dis.</source><year>2018</year><volume>10</volume><fpage>3141</fpage><lpage>3155</lpage><pub-id pub-id-type="doi">10.21037/jtd.2018.04.79</pub-id><pub-id pub-id-type="pmid">29997983</pub-id>
</element-citation></ref><ref id="B8-viruses-16-01830"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Halleck</surname><given-names>F.</given-names></name>
<name><surname>Friedersdorff</surname><given-names>F.</given-names></name>
<name><surname>Fuller</surname><given-names>T.F.</given-names></name>
<name><surname>Matz</surname><given-names>M.</given-names></name>
<name><surname>Huber</surname><given-names>L.</given-names></name>
<name><surname>D&#x000fc;rr</surname><given-names>M.</given-names></name>
<name><surname>Sch&#x000fc;tz</surname><given-names>M.</given-names></name>
<name><surname>Budde</surname><given-names>K.</given-names></name>
</person-group><article-title>New Perspectives of Immunosuppression</article-title><source>Transplant. Proc.</source><year>2013</year><volume>45</volume><fpage>1224</fpage><lpage>1231</lpage><pub-id pub-id-type="doi">10.1016/j.transproceed.2013.02.033</pub-id><pub-id pub-id-type="pmid">23622665</pub-id>
</element-citation></ref><ref id="B9-viruses-16-01830"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bamoulid</surname><given-names>J.</given-names></name>
<name><surname>Staeck</surname><given-names>O.</given-names></name>
<name><surname>Halleck</surname><given-names>F.</given-names></name>
<name><surname>Khadzhynov</surname><given-names>D.</given-names></name>
<name><surname>Brakemeier</surname><given-names>S.</given-names></name>
<name><surname>D&#x000fc;rr</surname><given-names>M.</given-names></name>
<name><surname>Budde</surname><given-names>K.</given-names></name>
</person-group><article-title>The need for minimization strategies: Current problems of immunosuppression</article-title><source>Transpl. Int.</source><year>2015</year><volume>28</volume><fpage>891</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1111/tri.12553</pub-id><pub-id pub-id-type="pmid">25752992</pub-id>
</element-citation></ref><ref id="B10-viruses-16-01830"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Mohanraj</surname><given-names>B.S.</given-names></name>
<name><surname>Rangnekar</surname><given-names>A.S.</given-names></name>
<name><surname>Timpone</surname><given-names>J.G.</given-names></name>
</person-group><article-title>Infections in Liver Transplantation</article-title><source>Principles and Practice of Transplant Infectious Diseases</source><person-group person-group-type="editor">
<name><surname>Safdar</surname><given-names>A.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2019</year><fpage>41</fpage><lpage>72</lpage></element-citation></ref><ref id="B11-viruses-16-01830"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wadei</surname><given-names>H.M.</given-names></name>
<name><surname>Burcin Taner</surname><given-names>C.</given-names></name>
<name><surname>Keaveny</surname><given-names>A.P.</given-names></name>
<name><surname>Mai</surname><given-names>M.L.</given-names></name>
<name><surname>Hodge</surname><given-names>D.O.</given-names></name>
<name><surname>White</surname><given-names>L.J.</given-names></name>
<name><surname>Harnois</surname><given-names>D.M.</given-names></name>
<name><surname>Mao</surname><given-names>S.A.</given-names></name>
<name><surname>Jarmi</surname><given-names>T.</given-names></name>
<name><surname>Croome</surname><given-names>K.P.</given-names></name>
</person-group><article-title>The changing impact of pre-liver transplant renal dysfunction on post-transplant survival: Results of 2 decades from a single center</article-title><source>Ann. Hepatol.</source><year>2021</year><volume>24</volume><fpage>100317</fpage><pub-id pub-id-type="doi">10.1016/j.aohep.2021.100317</pub-id><pub-id pub-id-type="pmid">33545403</pub-id>
</element-citation></ref><ref id="B12-viruses-16-01830"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gleisner</surname><given-names>A.L.</given-names></name>
<name><surname>Jung</surname><given-names>H.</given-names></name>
<name><surname>Lentine</surname><given-names>K.L.</given-names></name>
<name><surname>Tuttle-Newhall</surname><given-names>J.</given-names></name>
</person-group><article-title>Renal Dysfunction in Liver Transplant Candidates: Evaluation, Classification and Management in Contemporary Practice</article-title><source>J. Nephrol. Ther.</source><year>2012</year><volume>6</volume><issue>(Suppl. 4)</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.4172/2161-0959.S4-006</pub-id></element-citation></ref><ref id="B13-viruses-16-01830"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martin</surname><given-names>A.P.</given-names></name>
<name><surname>Bartels</surname><given-names>M.</given-names></name>
<name><surname>Hauss</surname><given-names>J.</given-names></name>
<name><surname>Fangmann</surname><given-names>J.</given-names></name>
</person-group><article-title>Overview of the MELD score and the UNOS adult liver allocation system</article-title><source>Transpl. Proc.</source><year>2007</year><volume>39</volume><fpage>3169</fpage><lpage>3174</lpage><pub-id pub-id-type="doi">10.1016/j.transproceed.2007.04.025</pub-id><pub-id pub-id-type="pmid">18089345</pub-id>
</element-citation></ref><ref id="B14-viruses-16-01830"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raja</surname><given-names>K.</given-names></name>
<name><surname>Panackel</surname><given-names>C.</given-names></name>
</person-group><article-title>Post Liver Transplant Renal Dysfunction-Evaluation, Management and Immunosuppressive Practice</article-title><source>J. Clin. Exp. Hepatol.</source><year>2024</year><volume>14</volume><fpage>101306</fpage><pub-id pub-id-type="doi">10.1016/j.jceh.2023.101306</pub-id><pub-id pub-id-type="pmid">38274509</pub-id>
</element-citation></ref><ref id="B15-viruses-16-01830"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pacheco</surname><given-names>M.P.</given-names></name>
<name><surname>Carneiro-D&#x02019;Albuquerque</surname><given-names>L.A.</given-names></name>
<name><surname>Mazo</surname><given-names>D.F.</given-names></name>
</person-group><article-title>Current aspects of renal dysfunction after liver transplantation</article-title><source>World J. Hepatol.</source><year>2022</year><volume>14</volume><fpage>45</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.4254/wjh.v14.i1.45</pub-id><pub-id pub-id-type="pmid">35126839</pub-id>
</element-citation></ref><ref id="B16-viruses-16-01830"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhanji</surname><given-names>R.A.</given-names></name>
<name><surname>Chow</surname><given-names>J.</given-names></name>
<name><surname>Ma</surname><given-names>M.</given-names></name>
<name><surname>Pannu</surname><given-names>N.</given-names></name>
<name><surname>Bain</surname><given-names>V.G.</given-names></name>
<name><surname>Kneteman</surname><given-names>N.</given-names></name>
<name><surname>Montano-Loza</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Post-liver transplantation chronic kidney disease is associated with increased cardiovascular disease risk and poor survival</article-title><source>Transpl. Int.</source><year>2021</year><volume>34</volume><fpage>2824</fpage><lpage>2833</lpage><pub-id pub-id-type="doi">10.1111/tri.14154</pub-id><pub-id pub-id-type="pmid">34738667</pub-id>
</element-citation></ref><ref id="B17-viruses-16-01830"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Horvatits</surname><given-names>T.</given-names></name>
<name><surname>Pischke</surname><given-names>S.</given-names></name>
<name><surname>Proske</surname><given-names>V.M.</given-names></name>
<name><surname>Fischer</surname><given-names>L.</given-names></name>
<name><surname>Scheidat</surname><given-names>S.</given-names></name>
<name><surname>Thaiss</surname><given-names>F.</given-names></name>
<name><surname>Fuhrmann</surname><given-names>V.</given-names></name>
<name><surname>Lohse</surname><given-names>A.W.</given-names></name>
<name><surname>Nashan</surname><given-names>B.</given-names></name>
<name><surname>Sterneck</surname><given-names>M.</given-names></name>
</person-group><article-title>Outcome and natural course of renal dysfunction in liver transplant recipients with severely impaired kidney function prior to transplantation</article-title><source>United Eur. Gastroenterol. J.</source><year>2018</year><volume>6</volume><fpage>104</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1177/2050640617707089</pub-id></element-citation></ref><ref id="B18-viruses-16-01830"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bahirwani</surname><given-names>R.</given-names></name>
<name><surname>Reddy</surname><given-names>K.R.</given-names></name>
</person-group><article-title>Outcomes after liver transplantation: Chronic kidney disease</article-title><source>Liver Transpl.</source><year>2009</year><volume>15</volume><issue>(Suppl. 2)</issue><fpage>S70</fpage><lpage>S74</lpage><pub-id pub-id-type="doi">10.1002/lt.21900</pub-id><pub-id pub-id-type="pmid">19876956</pub-id>
</element-citation></ref><ref id="B19-viruses-16-01830"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Balegamire</surname><given-names>S.J.</given-names></name>
<name><surname>McClymont</surname><given-names>E.</given-names></name>
<name><surname>Croteau</surname><given-names>A.</given-names></name>
<name><surname>Dodin</surname><given-names>P.</given-names></name>
<name><surname>Gantt</surname><given-names>S.</given-names></name>
<name><surname>Besharati</surname><given-names>A.A.</given-names></name>
<name><surname>Renaud</surname><given-names>C.</given-names></name>
<name><surname>M&#x000e2;sse</surname><given-names>B.</given-names></name>
<name><surname>Boucoiran</surname><given-names>I.</given-names></name>
</person-group><article-title>Prevalence, incidence, and risk factors associated with cytomegalovirus infection in healthcare and childcare worker: A systematic review and meta-analysis</article-title><source>Syst. Rev.</source><year>2022</year><volume>11</volume><fpage>131</fpage><pub-id pub-id-type="doi">10.1186/s13643-022-02004-4</pub-id><pub-id pub-id-type="pmid">35754052</pub-id>
</element-citation></ref><ref id="B20-viruses-16-01830"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Razonable</surname><given-names>R.R.</given-names></name>
<name><surname>Humar</surname><given-names>A.</given-names></name>
</person-group><article-title>Cytomegalovirus in solid organ transplant recipients&#x02014;Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice</article-title><source>Clin. Transplant.</source><year>2019</year><volume>33</volume><fpage>e13512</fpage><pub-id pub-id-type="doi">10.1111/ctr.13512</pub-id><pub-id pub-id-type="pmid">30817026</pub-id>
</element-citation></ref><ref id="B21-viruses-16-01830"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramanan</surname><given-names>P.</given-names></name>
<name><surname>Razonable</surname><given-names>R.R.</given-names></name>
</person-group><article-title>Cytomegalovirus infections in solid organ transplantation: A review</article-title><source>Infect. Chemother.</source><year>2013</year><volume>45</volume><fpage>260</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.3947/ic.2013.45.3.260</pub-id><pub-id pub-id-type="pmid">24396627</pub-id>
</element-citation></ref><ref id="B22-viruses-16-01830"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rashidi-Alavijeh</surname><given-names>J.</given-names></name>
<name><surname>Cr&#x000e4;mer</surname><given-names>J.C.</given-names></name>
<name><surname>Sauter</surname><given-names>H.L.</given-names></name>
<name><surname>Willuweit</surname><given-names>K.</given-names></name>
<name><surname>Straub</surname><given-names>K.</given-names></name>
<name><surname>Wedemeyer</surname><given-names>H.</given-names></name>
<name><surname>Herzer</surname><given-names>K.</given-names></name>
</person-group><article-title>Primary sclerosing cholangitis as an independent risk factor for cytomegalovirus infection after liver transplant</article-title><source>Transpl. Infect. Dis.</source><year>2021</year><volume>23</volume><fpage>e13553</fpage><pub-id pub-id-type="doi">10.1111/tid.13553</pub-id><pub-id pub-id-type="pmid">33368987</pub-id>
</element-citation></ref><ref id="B23-viruses-16-01830"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wreghitt</surname><given-names>T.G.</given-names></name>
<name><surname>Teare</surname><given-names>E.L.</given-names></name>
<name><surname>Sule</surname><given-names>O.</given-names></name>
<name><surname>Devi</surname><given-names>R.</given-names></name>
<name><surname>Rice</surname><given-names>P.</given-names></name>
</person-group><article-title>Cytomegalovirus Infection in Immunocompetent Patients</article-title><source>Clin. Infect. Dis.</source><year>2003</year><volume>37</volume><fpage>1603</fpage><lpage>1606</lpage><pub-id pub-id-type="doi">10.1086/379711</pub-id><pub-id pub-id-type="pmid">14689339</pub-id>
</element-citation></ref><ref id="B24-viruses-16-01830"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rafailidis</surname><given-names>P.I.</given-names></name>
<name><surname>Mourtzoukou</surname><given-names>E.G.</given-names></name>
<name><surname>Varbobitis</surname><given-names>I.C.</given-names></name>
<name><surname>Falagas</surname><given-names>M.E.</given-names></name>
</person-group><article-title>Severe cytomegalovirus infection in apparently immunocompetent patients: A systematic review</article-title><source>Virol. J.</source><year>2008</year><volume>5</volume><fpage>47</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-5-47</pub-id><pub-id pub-id-type="pmid">18371229</pub-id>
</element-citation></ref><ref id="B25-viruses-16-01830"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Omari</surname><given-names>A.</given-names></name>
<name><surname>Aljamaan</surname><given-names>F.</given-names></name>
<name><surname>Alhazzani</surname><given-names>W.</given-names></name>
<name><surname>Salih</surname><given-names>S.</given-names></name>
<name><surname>Arabi</surname><given-names>Y.</given-names></name>
</person-group><article-title>Cytomegalovirus infection in immunocompetent critically ill adults: Literature review</article-title><source>Ann. Intensive Care</source><year>2016</year><volume>6</volume><fpage>110</fpage><pub-id pub-id-type="doi">10.1186/s13613-016-0207-8</pub-id><pub-id pub-id-type="pmid">27813024</pub-id>
</element-citation></ref><ref id="B26-viruses-16-01830"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lancini</surname><given-names>D.</given-names></name>
<name><surname>Faddy</surname><given-names>H.M.</given-names></name>
<name><surname>Flower</surname><given-names>R.</given-names></name>
<name><surname>Hogan</surname><given-names>C.</given-names></name>
</person-group><article-title>Cytomegalovirus disease in immunocompetent adults</article-title><source>Med. J. Aust.</source><year>2014</year><volume>201</volume><fpage>578</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.5694/mja14.00183</pub-id><pub-id pub-id-type="pmid">25390262</pub-id>
</element-citation></ref><ref id="B27-viruses-16-01830"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Requi&#x000e3;o-Moura</surname><given-names>L.R.</given-names></name>
<name><surname>de Matos</surname><given-names>A.C.</given-names></name>
<name><surname>Pacheco-Silva</surname><given-names>A.</given-names></name>
</person-group><article-title>Cytomegalovirus infection in renal transplantation: Clinical aspects, management and the perspectives</article-title><source>Einstein (Sao Paulo)</source><year>2015</year><volume>13</volume><fpage>142</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1590/S1679-45082015RW3175</pub-id><pub-id pub-id-type="pmid">25993081</pub-id>
</element-citation></ref><ref id="B28-viruses-16-01830"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wall</surname><given-names>N.A.</given-names></name>
<name><surname>Chue</surname><given-names>C.D.</given-names></name>
<name><surname>Edwards</surname><given-names>N.C.</given-names></name>
<name><surname>Pankhurst</surname><given-names>T.</given-names></name>
<name><surname>Harper</surname><given-names>L.</given-names></name>
<name><surname>Steeds</surname><given-names>R.P.</given-names></name>
<name><surname>Lauder</surname><given-names>S.</given-names></name>
<name><surname>Townend</surname><given-names>J.N.</given-names></name>
<name><surname>Moss</surname><given-names>P.</given-names></name>
<name><surname>Ferro</surname><given-names>C.J.</given-names></name>
</person-group><article-title>Cytomegalovirus Seropositivity Is Associated with Increased Arterial Stiffness in Patients with Chronic Kidney Disease</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e55686</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0055686</pub-id><pub-id pub-id-type="pmid">23451030</pub-id>
</element-citation></ref><ref id="B29-viruses-16-01830"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Battegay</surname><given-names>E.J.</given-names></name>
<name><surname>Mihatsch</surname><given-names>M.J.</given-names></name>
<name><surname>Mazzucchelli</surname><given-names>L.</given-names></name>
<name><surname>Zollinger</surname><given-names>H.U.</given-names></name>
<name><surname>Gudat</surname><given-names>F.</given-names></name>
<name><surname>Thiel</surname><given-names>G.</given-names></name>
<name><surname>Heitz</surname><given-names>P.U.</given-names></name>
</person-group><article-title>Cytomegalovirus and kidney</article-title><source>Clin. Nephrol.</source><year>1988</year><volume>30</volume><fpage>239</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">2850879</pub-id>
</element-citation></ref><ref id="B30-viruses-16-01830"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chandra</surname><given-names>P.</given-names></name>
<name><surname>Kopp</surname><given-names>J.B.</given-names></name>
</person-group><article-title>Viruses and collapsing glomerulopathy: A brief critical review</article-title><source>Clin. Kidney J.</source><year>2012</year><volume>6</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1093/ckj/sft002</pub-id><pub-id pub-id-type="pmid">23372939</pub-id>
</element-citation></ref><ref id="B31-viruses-16-01830"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tomlinson</surname><given-names>L.</given-names></name>
<name><surname>Boriskin</surname><given-names>Y.</given-names></name>
<name><surname>McPhee</surname><given-names>I.</given-names></name>
<name><surname>Holwill</surname><given-names>S.</given-names></name>
<name><surname>Rice</surname><given-names>P.</given-names></name>
</person-group><article-title>Acute cytomegalovirus infection complicated by collapsing glomerulopathy</article-title><source>Nephrol. Dial. Transplant.</source><year>2003</year><volume>18</volume><fpage>187</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1093/ndt/18.1.187</pub-id><pub-id pub-id-type="pmid">12480980</pub-id>
</element-citation></ref><ref id="B32-viruses-16-01830"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bromfield</surname><given-names>M.</given-names></name>
<name><surname>McQuillan</surname><given-names>R.</given-names></name>
<name><surname>John</surname><given-names>R.</given-names></name>
<name><surname>Avila-Casado</surname><given-names>C.</given-names></name>
</person-group><article-title>The significance of tubuloreticular inclusions as a marker of systemic stimulation by interferons in a case of focal and segmental glomerulosclerosis associated with cytomegalovirus (CMV) infection</article-title><source>Clin. Kidney J.</source><year>2014</year><volume>7</volume><fpage>174</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1093/ckj/sft156</pub-id><pub-id pub-id-type="pmid">25852866</pub-id>
</element-citation></ref><ref id="B33-viruses-16-01830"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Masset</surname><given-names>C.</given-names></name>
<name><surname>Le Turnier</surname><given-names>P.</given-names></name>
<name><surname>Bressollette-Bodin</surname><given-names>C.</given-names></name>
<name><surname>Renaudin</surname><given-names>K.</given-names></name>
<name><surname>Raffi</surname><given-names>F.</given-names></name>
<name><surname>Dantal</surname><given-names>J.</given-names></name>
</person-group><article-title>Virus-Associated Nephropathies: A Narrative Review</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>12014</elocation-id><pub-id pub-id-type="doi">10.3390/ijms231912014</pub-id><pub-id pub-id-type="pmid">36233315</pub-id>
</element-citation></ref><ref id="B34-viruses-16-01830"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stevens</surname><given-names>P.E.</given-names></name>
<name><surname>Levin</surname><given-names>A.</given-names></name>
</person-group><article-title>Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline</article-title><source>Ann. Intern. Med.</source><year>2013</year><volume>158</volume><fpage>825</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-158-11-201306040-00007</pub-id><pub-id pub-id-type="pmid">23732715</pub-id>
</element-citation></ref><ref id="B35-viruses-16-01830"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Engelmann</surname><given-names>C.</given-names></name>
<name><surname>Sterneck</surname><given-names>M.</given-names></name>
<name><surname>Weiss</surname><given-names>K.H.</given-names></name>
<name><surname>Templin</surname><given-names>S.</given-names></name>
<name><surname>Zopf</surname><given-names>S.</given-names></name>
<name><surname>Denk</surname><given-names>G.</given-names></name>
<name><surname>Eurich</surname><given-names>D.</given-names></name>
<name><surname>Pratschke</surname><given-names>J.</given-names></name>
<name><surname>Weiss</surname><given-names>J.</given-names></name>
<name><surname>Braun</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Prevention and Management of CMV Infections after Liver Transplantation: Current Practice in German Transplant Centers</article-title><source>J. Clin. Med.</source><year>2020</year><volume>9</volume><elocation-id>2352</elocation-id><pub-id pub-id-type="doi">10.3390/jcm9082352</pub-id><pub-id pub-id-type="pmid">32717978</pub-id>
</element-citation></ref><ref id="B36-viruses-16-01830"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Habib</surname><given-names>S.</given-names></name>
<name><surname>Berk</surname><given-names>B.</given-names></name>
<name><surname>Chang</surname><given-names>C.C.</given-names></name>
<name><surname>Demetris</surname><given-names>A.J.</given-names></name>
<name><surname>Fontes</surname><given-names>P.</given-names></name>
<name><surname>Dvorchik</surname><given-names>I.</given-names></name>
<name><surname>Eghtesad</surname><given-names>B.</given-names></name>
<name><surname>Marcos</surname><given-names>A.</given-names></name>
<name><surname>Shakil</surname><given-names>A.O.</given-names></name>
</person-group><article-title>MELD and prediction of post-liver transplantation survival</article-title><source>Liver Transpl.</source><year>2006</year><volume>12</volume><fpage>440</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1002/lt.20721</pub-id><pub-id pub-id-type="pmid">16498643</pub-id>
</element-citation></ref><ref id="B37-viruses-16-01830"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ling</surname><given-names>Q.</given-names></name>
<name><surname>Dai</surname><given-names>H.</given-names></name>
<name><surname>Zhuang</surname><given-names>R.</given-names></name>
<name><surname>Shen</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Zheng</surname><given-names>S.</given-names></name>
</person-group><article-title>Predicting short-term survival after liver transplantation on eight score systems: A national report from China Liver Transplant Registry</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>42253</elocation-id><pub-id pub-id-type="doi">10.1038/srep42253</pub-id><pub-id pub-id-type="pmid">28198820</pub-id>
</element-citation></ref><ref id="B38-viruses-16-01830"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Romano</surname><given-names>T.G.</given-names></name>
<name><surname>Schmidtbauer</surname><given-names>I.</given-names></name>
<name><surname>Silva</surname><given-names>F.M.d.Q.</given-names></name>
<name><surname>Pompilio</surname><given-names>C.E.</given-names></name>
<name><surname>D&#x02019;Albuquerque</surname><given-names>L.A.C.</given-names></name>
<name><surname>Macedo</surname><given-names>E.</given-names></name>
</person-group><article-title>Role of MELD Score and Serum Creatinine as Prognostic Tools for the Development of Acute Kidney Injury after Liver Transplantation</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e64089</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0064089</pub-id><pub-id pub-id-type="pmid">23717537</pub-id>
</element-citation></ref><ref id="B39-viruses-16-01830"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al Mana</surname><given-names>H.</given-names></name>
<name><surname>Yassine</surname><given-names>H.M.</given-names></name>
<name><surname>Younes</surname><given-names>N.N.</given-names></name>
<name><surname>Al-Mohannadi</surname><given-names>A.</given-names></name>
<name><surname>Al-Sadeq</surname><given-names>D.W.</given-names></name>
<name><surname>Alhababi</surname><given-names>D.</given-names></name>
<name><surname>Nasser</surname><given-names>E.A.</given-names></name>
<name><surname>Nasrallah</surname><given-names>G.K.</given-names></name>
</person-group><article-title>The Current Status of Cytomegalovirus (CMV) Prevalence in the MENA Region: A Systematic Review</article-title><source>Pathogens</source><year>2019</year><volume>8</volume><elocation-id>213</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens8040213</pub-id><pub-id pub-id-type="pmid">31683687</pub-id>
</element-citation></ref><ref id="B40-viruses-16-01830"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zuhair</surname><given-names>M.</given-names></name>
<name><surname>Smit</surname><given-names>G.S.A.</given-names></name>
<name><surname>Wallis</surname><given-names>G.</given-names></name>
<name><surname>Jabbar</surname><given-names>F.</given-names></name>
<name><surname>Smith</surname><given-names>C.</given-names></name>
<name><surname>Devleesschauwer</surname><given-names>B.</given-names></name>
<name><surname>Griffiths</surname><given-names>P.</given-names></name>
</person-group><article-title>Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis</article-title><source>Rev. Med. Virol.</source><year>2019</year><volume>29</volume><fpage>e2034</fpage><pub-id pub-id-type="doi">10.1002/rmv.2034</pub-id><pub-id pub-id-type="pmid">30706584</pub-id>
</element-citation></ref><ref id="B41-viruses-16-01830"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gliga</surname><given-names>S.</given-names></name>
<name><surname>Fiedler</surname><given-names>M.</given-names></name>
<name><surname>Dornieden</surname><given-names>T.</given-names></name>
<name><surname>Achterfeld</surname><given-names>A.</given-names></name>
<name><surname>Paul</surname><given-names>A.</given-names></name>
<name><surname>Horn</surname><given-names>P.A.</given-names></name>
<name><surname>Herzer</surname><given-names>K.</given-names></name>
<name><surname>Lindemann</surname><given-names>M.</given-names></name>
</person-group><article-title>Comparison of Three Cellular Assays to Predict the Course of CMV Infection in Liver Transplant Recipients</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>88</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9020088</pub-id><pub-id pub-id-type="pmid">33504093</pub-id>
</element-citation></ref><ref id="B42-viruses-16-01830"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pajenda</surname><given-names>S.</given-names></name>
<name><surname>Kapps</surname><given-names>S.</given-names></name>
<name><surname>Gerges</surname><given-names>D.</given-names></name>
<name><surname>Hoermann</surname><given-names>G.</given-names></name>
<name><surname>Wagner</surname><given-names>L.</given-names></name>
<name><surname>Buchtele</surname><given-names>N.</given-names></name>
<name><surname>Geist</surname><given-names>B.</given-names></name>
<name><surname>Strassl</surname><given-names>R.</given-names></name>
<name><surname>Schmidt</surname><given-names>A.</given-names></name>
<name><surname>Winnicki</surname><given-names>W.</given-names></name>
</person-group><article-title>Cytomegalovirus in urinary sediment in patients with acute kidney injury</article-title><source>BMC Nephrol.</source><year>2021</year><volume>22</volume><elocation-id>169</elocation-id><pub-id pub-id-type="doi">10.1186/s12882-021-02377-z</pub-id><pub-id pub-id-type="pmid">33962580</pub-id>
</element-citation></ref><ref id="B43-viruses-16-01830"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Albillos</surname><given-names>A.</given-names></name>
<name><surname>Lario</surname><given-names>M.</given-names></name>
<name><surname>&#x000c1;lvarez-Mon</surname><given-names>M.</given-names></name>
</person-group><article-title>Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance</article-title><source>J. Hepatol.</source><year>2014</year><volume>61</volume><fpage>1385</fpage><lpage>1396</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2014.08.010</pub-id><pub-id pub-id-type="pmid">25135860</pub-id>
</element-citation></ref><ref id="B44-viruses-16-01830"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Irvine</surname><given-names>K.M.</given-names></name>
<name><surname>Ratnasekera</surname><given-names>I.</given-names></name>
<name><surname>Powell</surname><given-names>E.E.</given-names></name>
<name><surname>Hume</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Causes and Consequences of Innate Immune Dysfunction in Cirrhosis</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><elocation-id>293</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00293</pub-id><pub-id pub-id-type="pmid">30873165</pub-id>
</element-citation></ref><ref id="B45-viruses-16-01830"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>T.</given-names></name>
<name><surname>Chouik</surname><given-names>Y.</given-names></name>
<name><surname>Leboss&#x000e9;</surname><given-names>F.</given-names></name>
<name><surname>Khamri</surname><given-names>W.</given-names></name>
</person-group><article-title>Dysfunctions of Circulating Adaptive Immune Cells in End-Stage Liver Disease</article-title><source>Livers</source><year>2023</year><volume>3</volume><fpage>369</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.3390/livers3030028</pub-id></element-citation></ref><ref id="B46-viruses-16-01830"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Faivre</surname><given-names>M.</given-names></name>
<name><surname>Cottet</surname><given-names>V.</given-names></name>
<name><surname>Bour</surname><given-names>J.B.</given-names></name>
<name><surname>Richou</surname><given-names>C.</given-names></name>
<name><surname>Valmary-Degano</surname><given-names>S.</given-names></name>
<name><surname>Thiefin</surname><given-names>G.</given-names></name>
<name><surname>Andreoletti</surname><given-names>L.</given-names></name>
<name><surname>Geist</surname><given-names>C.</given-names></name>
<name><surname>Schvoerer</surname><given-names>E.</given-names></name>
<name><surname>Malv&#x000e9;</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Impact of Cytomegalovirus Infection on the Outcome of Patients With Cirrhosis: A Preliminary Study</article-title><source>J. Clin. Gastroenterol.</source><year>2019</year><volume>53</volume><fpage>236</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1097/MCG.0000000000001039</pub-id><pub-id pub-id-type="pmid">30383568</pub-id>
</element-citation></ref><ref id="B47-viruses-16-01830"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lizaola-Mayo</surname><given-names>B.C.</given-names></name>
<name><surname>Rodriguez</surname><given-names>E.A.</given-names></name>
</person-group><article-title>Cytomegalovirus infection after liver transplantation</article-title><source>World J. Transpl.</source><year>2020</year><volume>10</volume><fpage>183</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.5500/wjt.v10.i7.183</pub-id></element-citation></ref><ref id="B48-viruses-16-01830"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yadav</surname><given-names>S.K.</given-names></name>
<name><surname>Saigal</surname><given-names>S.</given-names></name>
<name><surname>Choudhary</surname><given-names>N.S.</given-names></name>
<name><surname>Saha</surname><given-names>S.</given-names></name>
<name><surname>Kumar</surname><given-names>N.</given-names></name>
<name><surname>Soin</surname><given-names>A.S.</given-names></name>
</person-group><article-title>Cytomegalovirus Infection in Liver Transplant Recipients: Current Approach to Diagnosis and Management</article-title><source>J. Clin. Exp. Hepatol.</source><year>2017</year><volume>7</volume><fpage>144</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.jceh.2017.05.011</pub-id><pub-id pub-id-type="pmid">28663679</pub-id>
</element-citation></ref><ref id="B49-viruses-16-01830"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kanj</surname><given-names>S.S.</given-names></name>
<name><surname>Sharara</surname><given-names>A.I.</given-names></name>
<name><surname>Clavien</surname><given-names>P.-A.</given-names></name>
<name><surname>Hamilton</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Cytomegalovirus Infection Following Liver Transplantation: Review of the Literature</article-title><source>Clin. Infect. Dis.</source><year>1996</year><volume>22</volume><fpage>537</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1093/clinids/22.3.537</pub-id><pub-id pub-id-type="pmid">8852975</pub-id>
</element-citation></ref><ref id="B50-viruses-16-01830"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yadav</surname><given-names>D.K.</given-names></name>
<name><surname>Adhikari</surname><given-names>V.P.</given-names></name>
<name><surname>Yadav</surname><given-names>R.K.</given-names></name>
<name><surname>Singh</surname><given-names>A.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Pandit</surname><given-names>P.</given-names></name>
<name><surname>Ling</surname><given-names>Q.</given-names></name>
<name><surname>Liang</surname><given-names>T.</given-names></name>
</person-group><article-title>Antiviral prophylaxis or preemptive therapy for cytomegalovirus after liver transplantation?: A systematic review and meta-analysis</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>953210</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.953210</pub-id><pub-id pub-id-type="pmid">36439159</pub-id>
</element-citation></ref><ref id="B51-viruses-16-01830"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>N.</given-names></name>
<name><surname>Winston</surname><given-names>D.</given-names></name>
<name><surname>Razonable</surname><given-names>R.R.</given-names></name>
<name><surname>Lyon III</surname><given-names>G.M.</given-names></name>
<name><surname>Silveira</surname><given-names>F.P.</given-names></name>
<name><surname>Wagener</surname><given-names>M.</given-names></name>
<name><surname>Limaye</surname><given-names>A.P.</given-names></name>
</person-group><article-title>LB21. Preemptive Therapy (PET) vs. Prophylaxis for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Donor Seropositive/Recipient Seronegative (D+R&#x02212;) Liver Transplant Recipients (LTR): A NIH-Sponsored, Randomized, Controlled, Multicenter Trial</article-title><source>Open Forum Infect. Dis.</source><year>2018</year><volume>5</volume><fpage>S766</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofy229.2195</pub-id></element-citation></ref><ref id="B52-viruses-16-01830"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dobrer</surname><given-names>S.</given-names></name>
<name><surname>Sherwood</surname><given-names>K.R.</given-names></name>
<name><surname>Hirji</surname><given-names>I.</given-names></name>
<name><surname>Lan</surname><given-names>J.</given-names></name>
<name><surname>Gill</surname><given-names>J.</given-names></name>
<name><surname>Matic</surname><given-names>N.</given-names></name>
<name><surname>Keown</surname><given-names>P.A.</given-names></name>
</person-group><article-title>Viral load kinetics and the clinical consequences of cytomegalovirus in kidney transplantation</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1302627</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1302627</pub-id><pub-id pub-id-type="pmid">38361528</pub-id>
</element-citation></ref><ref id="B53-viruses-16-01830"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ossami Saidy</surname><given-names>R.R.</given-names></name>
<name><surname>Kollar</surname><given-names>S.</given-names></name>
<name><surname>Czigany</surname><given-names>Z.</given-names></name>
<name><surname>Dittrich</surname><given-names>L.</given-names></name>
<name><surname>Raschzok</surname><given-names>N.</given-names></name>
<name><surname>Globke</surname><given-names>B.</given-names></name>
<name><surname>Sch&#x000f6;ning</surname><given-names>W.</given-names></name>
<name><surname>&#x000d6;llinger</surname><given-names>R.</given-names></name>
<name><surname>Lurje</surname><given-names>G.</given-names></name>
<name><surname>Pratschke</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Detrimental impact of immunosuppressive burden on clinical course in patients with Cytomegalovirus infection after liver transplantation</article-title><source>Transpl. Infect. Dis.</source><year>2024</year><volume>26</volume><fpage>e14196</fpage><pub-id pub-id-type="doi">10.1111/tid.14196</pub-id><pub-id pub-id-type="pmid">38010975</pub-id>
</element-citation></ref><ref id="B54-viruses-16-01830"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bosch</surname><given-names>W.</given-names></name>
<name><surname>Heckman</surname><given-names>M.G.</given-names></name>
<name><surname>Diehl</surname><given-names>N.N.</given-names></name>
<name><surname>Shalev</surname><given-names>J.A.</given-names></name>
<name><surname>Pungpapong</surname><given-names>S.</given-names></name>
<name><surname>Hellinger</surname><given-names>W.C.</given-names></name>
</person-group><article-title>Association of Cytomegalovirus Infection and Disease With Death and Graft Loss After Liver Transplant in High-Risk Recipients</article-title><source>Am. J. Transplant.</source><year>2011</year><volume>11</volume><fpage>2181</fpage><lpage>2189</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2011.03618.x</pub-id><pub-id pub-id-type="pmid">21827609</pub-id>
</element-citation></ref><ref id="B55-viruses-16-01830"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vichot</surname><given-names>A.A.</given-names></name>
<name><surname>Formica</surname><given-names>R.N.</given-names><suffix>Jr.</suffix></name>
<name><surname>Moeckel</surname><given-names>G.W.</given-names></name>
</person-group><article-title>Cytomegalovirus glomerulopathy and cytomegalovirus interstitial nephritis on sequential transplant kidney biopsies</article-title><source>Am. J. Kidney Dis.</source><year>2014</year><volume>63</volume><fpage>536</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2013.08.021</pub-id><pub-id pub-id-type="pmid">24568687</pub-id>
</element-citation></ref><ref id="B56-viruses-16-01830"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Onuigbo</surname><given-names>M.</given-names></name>
<name><surname>Haririan</surname><given-names>A.</given-names></name>
<name><surname>Ramos</surname><given-names>E.</given-names></name>
<name><surname>Klassen</surname><given-names>D.</given-names></name>
<name><surname>Wali</surname><given-names>R.</given-names></name>
<name><surname>Drachenberg</surname><given-names>C.</given-names></name>
</person-group><article-title>Cytomegalovirus&#x02010;Induced Glomerular Vasculopathy in Renal Allografts: A Report of Two Cases</article-title><source>Am. J. Transplant.</source><year>2002</year><volume>2</volume><fpage>684</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1034/j.1600-6143.2002.20717.x</pub-id><pub-id pub-id-type="pmid">12201373</pub-id>
</element-citation></ref><ref id="B57-viruses-16-01830"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grover</surname><given-names>V.</given-names></name>
<name><surname>Gaiki</surname><given-names>M.R.</given-names></name>
<name><surname>DeVita</surname><given-names>M.V.</given-names></name>
<name><surname>Schwimmer</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Cytomegalovirus-induced collapsing focal segmental glomerulosclerosis</article-title><source>Clin. Kidney J.</source><year>2012</year><volume>6</volume><fpage>71</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1093/ckj/sfs097</pub-id><pub-id pub-id-type="pmid">27818753</pub-id>
</element-citation></ref><ref id="B58-viruses-16-01830"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kirkham</surname><given-names>F.</given-names></name>
<name><surname>Pera</surname><given-names>A.</given-names></name>
<name><surname>Simanek</surname><given-names>A.M.</given-names></name>
<name><surname>Bano</surname><given-names>A.</given-names></name>
<name><surname>Morrow</surname><given-names>G.</given-names></name>
<name><surname>Reus</surname><given-names>B.</given-names></name>
<name><surname>Caserta</surname><given-names>S.</given-names></name>
<name><surname>Smith</surname><given-names>H.E.</given-names></name>
<name><surname>Davies</surname><given-names>K.A.</given-names></name>
<name><surname>Rajkumar</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Cytomegalovirus infection is associated with an increase in aortic stiffness in older men which may be mediated in part by CD4 memory T-cells</article-title><source>Theranostics</source><year>2021</year><volume>11</volume><fpage>5728</fpage><lpage>5741</lpage><pub-id pub-id-type="doi">10.7150/thno.58356</pub-id><pub-id pub-id-type="pmid">33897878</pub-id>
</element-citation></ref><ref id="B59-viruses-16-01830"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Herrera</surname><given-names>G.A.</given-names></name>
<name><surname>Alexander</surname><given-names>R.W.</given-names></name>
<name><surname>Cooley</surname><given-names>C.F.</given-names></name>
<name><surname>Luke</surname><given-names>R.G.</given-names></name>
<name><surname>Kelly</surname><given-names>D.R.</given-names></name>
<name><surname>Curtis</surname><given-names>J.J.</given-names></name>
<name><surname>Gockerman</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Cytomegalovirus glomerulopathy: A controversial lesion</article-title><source>Kidney Int.</source><year>1986</year><volume>29</volume><fpage>725</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1038/ki.1986.58</pub-id><pub-id pub-id-type="pmid">3009956</pub-id>
</element-citation></ref><ref id="B60-viruses-16-01830"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>P.Y.</given-names></name>
<name><surname>Cheng</surname><given-names>S.B.</given-names></name>
<name><surname>Lin</surname><given-names>C.C.</given-names></name>
<name><surname>Lin</surname><given-names>C.H.</given-names></name>
<name><surname>Chang</surname><given-names>S.N.</given-names></name>
<name><surname>Cheng</surname><given-names>C.Y.</given-names></name>
<name><surname>Shi</surname><given-names>Z.Y.</given-names></name>
<name><surname>Tung</surname><given-names>K.C.</given-names></name>
<name><surname>Wu</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Cytomegalovirus Disease After Liver Transplantation: A Nationwide Population-Based Study</article-title><source>Transplant. Proc.</source><year>2014</year><volume>46</volume><fpage>832</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1016/j.transproceed.2013.12.009</pub-id><pub-id pub-id-type="pmid">24767359</pub-id>
</element-citation></ref><ref id="B61-viruses-16-01830"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farouk</surname><given-names>S.S.</given-names></name>
<name><surname>Rein</surname><given-names>J.L.</given-names></name>
</person-group><article-title>The Many Faces of Calcineurin Inhibitor Toxicity-What the FK?</article-title><source>Adv. Chronic Kidney Dis.</source><year>2020</year><volume>27</volume><fpage>56</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1053/j.ackd.2019.08.006</pub-id><pub-id pub-id-type="pmid">32147003</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-16-01830-f001"><label>Figure 1</label><caption><p>Constitution of groups for analysis of impact of CMV infection. For the analysis of subgroups in regard to exposition to CMV, three groups were defined. Group 1 is formed by patients without any recorded CMV infection; in group 2, patients were only CMV-IgG-positive at LT; group 3 was formed by patients that had recorded CMV infection after LT.</p></caption><graphic xlink:href="viruses-16-01830-g001" position="float"/></fig><fig position="float" id="viruses-16-01830-f002"><label>Figure 2</label><caption><p>Course of median eGFR over time. There was a decrease in overall renal function regarding median eGFR over time in the overall cohort (<bold>a</bold>). eGFR showed different dynamics depending on occurrence of CMV infection (<bold>b</bold>,<bold>c</bold>). For details on eGFR at given time points, see <xref rid="app1-viruses-16-01830" ref-type="app">Supplementary Materials, Table S1</xref>. LT&#x02014;liver transplantation; CMV&#x02014;cytomegalovirus; ~ indicates interpolation line.</p></caption><graphic xlink:href="viruses-16-01830-g002" position="float"/></fig><fig position="float" id="viruses-16-01830-f003"><label>Figure 3</label><caption><p>Survival analysis after LT. Kaplan&#x02013;Meier analysis revealed significantly impaired overall survival after LT in patients with recorded CMV infection after transplantation (<bold>a</bold>). Subgroup analysis for patients without any recorded CMV exposure (Group 1) compared to patients with CMV IgG positivity prior to LT (group 2) or patients with CMV infection after LT (group 3) did not show statistically significant differences (<bold>b</bold>). Patients with more than one episode of CMV viremia were found to have impaired overall survival after LT (<bold>c</bold>).</p></caption><graphic xlink:href="viruses-16-01830-g003" position="float"/></fig><table-wrap position="float" id="viruses-16-01830-t001"><object-id pub-id-type="pii">viruses-16-01830-t001_Table 1</object-id><label>Table 1</label><caption><p>Patient cohort&#x02019;s characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patient Cohort (<italic toggle="yes">n</italic> = 745)</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median age at LT in years (min&#x02013;max)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.3 (19.3&#x02013;74.2)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sex (%)<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;Male<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>494 (66.3)<break/>251 (33.7)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Indication for LT (%)<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;ALD<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;Viral hepatitis<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;AIH/PSC/PBC<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;NASH/cryptogenic cirrhosis<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;HCC/CCA<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;ALF<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;Others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>304 (40.8)<break/>168 (22.6)<break/>97 (13.0)<break/>58 (7.8)<break/>32 (4.3)<break/>25 (3.4)<break/>61 (8.2)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median MELD (min&#x02013;max)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 (6&#x02013;40)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Comorbidities at LT (%)<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;Cardiovascular disease<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;Diabetes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>79 (10.6)<break/>65 (8.7)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median eGFR at LT mL/min (min&#x02013;max)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84.8 (5&#x02013;150)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CKD at LT (%)<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;I<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;II<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;III<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;IV<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>346 (46.4)<break/>237 (31.8)<break/>118 (15.8)<break/>28 (3.8)<break/>16 (2.1)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Donor-recipient CMV risk stratification (%)<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;R negative/D negative<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;R negative/D positive<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;R positive/D negative<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;R positive/D positive<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;Missing data</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>82 (11.0)<break/>146 (19.6)<break/>174 (23.4)<break/>257 (34.5)<break/>86 (11.5)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CMV infections after LT (%)<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;Time from LT<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;&#x0003c;90 days<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;&#x0003e;90 days<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;Median viral load in IU/mL (min&#x02013;max)<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;At diagnosis<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;Peak<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;Manifestation (%)<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;CMV viremia<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;CMV syndrome<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;CMV tissue invasion<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;Treatment (%)<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;Observation only<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;IS reduction<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;(val)ganciclovir</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">271 (36.4)<break/><break/>220 (81.2)<break/>51 (18.8)<break/><break/>3160 (10&#x02013;13,900,000)<break/>7335 (756&#x02013;13,900,000)<break/><break/>203 (27.2)<break/>66 (8.9)<break/>2 (0.003)<break/><break/>61 (22.5)<break/>34 (12.5)<break/>176 (64.9)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maintenance IS after LT (%) <break/>&#x02003;&#x02003;&#x000a0;&#x000a0;CNI<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;Tacrolimus<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;Cyclosporin A<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;MMF<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;mTORI<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;Combination therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>725 (97.3)<break/>625 (83.8)<break/>100 (13.4)<break/>353 (47.4)<break/>81 (10.9)<break/>476 (63.9)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean time of follow-up in months (SD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">117.2 (58.3)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients deceased (%)<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;Cause of death<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;Graft failure<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;Neoplasms<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;Cardiovascular<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;Pulmonary<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;Infection<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;Neurological<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;Acute bleeding<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;Trauma<break/>&#x02003;&#x02003;&#x000a0;&#x000a0;&#x02003;&#x02003;&#x000a0;&#x000a0;Other</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">313 (42.0)<break/><break/>38 (5.1)<break/>108 (14.5)<break/>36 (4.8)<break/>9 (1.2)<break/>68 (9.2)<break/>7 (0.9)<break/>10 (1.3)<break/>5 (0.7)<break/>32 (4.3)</td></tr></tbody></table><table-wrap-foot><fn><p>LT&#x02014;liver transplantation; ALD&#x02014;alcoholic liver disease; AIH&#x02014;autoimmune hepatitis; PSC&#x02014;primary sclerosing cholangitis; PBC&#x02014;primary biliary cirrhosis; NASH&#x02014;non-alcoholic steatohepatitis; HCC&#x02014;hepatocellular carcinoma; CCA&#x02014;cholangiocellular carcinoma; ALF&#x02014;acute liver failure; eGFR&#x02014;estimated glomerular filtration rate; CKD&#x02014;chronic kidney disease; CMV&#x02014;cytomegalovirus; CNI&#x02014;calcineurin inhibitor; MMF&#x02014;mycophenolate mofetil; mTORI&#x02014;mammalian target of rapamycin inhibitor.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-16-01830-t002"><object-id pub-id-type="pii">viruses-16-01830-t002_Table 2</object-id><label>Table 2</label><caption><p>Impact of clinical parameters on eGFR and CKD prior to LT in univariate analysis. Clinical variables with putative impact on renal function using either the CKD classification or eGFR were explored.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Groups</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CKD I<break/><italic toggle="yes">n</italic> (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CKD II<break/><italic toggle="yes">n</italic> (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CKD III<break/><italic toggle="yes">n</italic> (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CKD IV<break/><italic toggle="yes">n</italic> (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CKD V<break/><italic toggle="yes">n</italic> (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">eGFR Prior to LT in mL/min<break/><break/>Median (Min&#x02013;Max) *</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02264;60 years<break/>&#x0003e;60 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">254 (50.3)<break/>92 (38.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">147 (29.1)<break/>90 (38.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72 (14.3)<break/>46 (19.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21 (4.2)<break/>7 (2.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (2.2)<break/>5 (2.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.0 (8&#x02013;150)<break/>81.4 (11&#x02013;131)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> = 0.011</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sex</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male<break/>Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">256 (51.8)<break/>90 (35.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">155 (31.4)<break/>82 (32.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67 (13.6)<break/>51 (20.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (2.6)<break/>15 (6.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (0.6)<break/>13 (5.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.0 (10&#x02013;150)<break/>71.4 (5&#x02013;137)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Indication for LT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ALD<break/>Viral hepatitis<break/>AIH/PSC/PBC<break/>NASH/cryptogenic cirrhosis<break/>HCC/CCA<break/>ALF<break/>Others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">128 (42.1)<break/>74 (44.0)<break/>55 (56.7)<break/>24 (41.1)<break/>20 (62.5)<break/>13 (52.0)<break/>32 (52.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">106 (34.9)<break/>60 (35.7)<break/>29 (29.9)<break/>16 (27.6)<break/>8 (25.0)<break/>4 (16.0)<break/>14 (23.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57 (18.8)<break/>25 (14.9)<break/>9 (9.3)<break/>12 (20.7)<break/>2 (6.3)<break/>3 (12.0)<break/>10 (16.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (3.0)<break/>6 (3.6)<break/>1 (1.0)<break/>3 (4.9)<break/>1 (3.1)<break/>5 (20.0)<break/>3 (4.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (1.3)<break/>3 (1.8)<break/>3 (5.2)<break/>3 (5.2)<break/>1 (3.1)<break/>0 (0)<break/>2(3.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">82.7 (10&#x02013;123)<break/>83.0 (12&#x02013;131)<break/>90.0 (11&#x02013;133)<break/>69.5 (8&#x02013;137)<break/>90.5 (12&#x02013;135)<break/>90.0 (17&#x02013;150)<break/>90.0 (5&#x02013;147)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.038</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cardiovascular disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 (29.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 (38.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 (25.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (6.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.008</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62.0 (11&#x02013;118)<break/>88.1 (5&#x02013;150)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diabetes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29 (44.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 (35.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (20.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.256</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78.4 (30&#x02013;130)<break/>85.4 (5&#x02013;150)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recipient CMV status</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CMV positive<break/>CMV negative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">209 (43.8)<break/>132 (52.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">153 (32.1)<break/>77 (30.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">82 (17.2)<break/>35 (13.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 (5.0)<break/>4 (1.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (2.4)<break/>6 (1.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.059</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.4 (8&#x02013;137)<break/>90.0 (5&#x02013;147)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.004</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median MELD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 (6&#x02013;40)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 (6&#x02013;40)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 (6&#x02013;40)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32 (15&#x02013;40)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36 (20&#x02013;40)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">r = &#x02212;0.323 **</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>LT&#x02014;liver transplantation; ALD&#x02014;alcoholic liver disease; AIH&#x02014;autoimmune hepatitis; PSC&#x02014;primary sclerosing cholangitis; PBC&#x02014;primary biliary cirrhosis; NASH&#x02014;non-alcoholic steatohepatitis; HCC&#x02014;hepatocellular carcinoma; CCA&#x02014;cholangiocellular carcinoma; ALF&#x02014;acute liver failure; CMV&#x02014;cytomegalovirus; MELD&#x02014;model of end-stage liver disease. * median and range only for categorical variables. ** Pearson correlation coefficient was calculated for correlation of metric MELD and eGFR).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-16-01830-t003"><object-id pub-id-type="pii">viruses-16-01830-t003_Table 3</object-id><label>Table 3</label><caption><p>Multivariate analysis of impact of variables on eGRF prior to LT.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Variable</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
<italic toggle="yes">p</italic>
</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Regression Coefficient</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">95% CI</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lower</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Upper</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age (ref.: &#x02264;60 years)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;7.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;11.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.17</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sex (ref.: male)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;12.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;16.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;8.34</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Indication for LT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.70</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cardiovascular disease<break/>(ref.: yes)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.004</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.96</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recipient CMV status<break/>(ref.: CMV negative)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.117</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;7.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.81</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MELD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.88</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.69</td></tr></tbody></table><table-wrap-foot><fn><p>LT&#x02014;liver transplantation; CMV&#x02014;cytomegalovirus.</p></fn></table-wrap-foot></table-wrap></floats-group></article>